Opinion

Video

Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment

A expert cardiologist delves into the insights gained from clinical trials assessing Cardiac Myosin inhibitors (CMIs) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), with a particular focus on the EXPLORER-HCM trial, which investigated the efficacy and safety of mavacamten in managing oHCM.

  1. What have we learned from clinical trials evaluating CMI’s for oHCM? Hutt et al 2024
Related Videos
Understanding Angioedema in Urticaria, with Jonathan Bernstein, MD
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Brian Lee, MD | Credit: AASLD
Transformations in Aortic Disease Management with Mehrdad Ghoreishi, MD | Image Credit: Baptist Health South Florida
Importance of Birch Triterpene Findings for Epidermolysis Bullosa, with Anna Bruckner, MD
Phase 3 Findings on Birch Triterpenes for Epidermolysis Bullosa, with Anna Bruckner, MD
© 2025 MJH Life Sciences

All rights reserved.